Wissenschaftliche Publikationen Suche Suche Autor/in Forschungsgruppe Veröffentlichungsdatum Suchen Sortieren nach RelevanceFrom A-ZAuthored onDate/Time RangeRelease date Reihenfolge AufsteigendAbsteigend Blankenstein, Thomas Prof. Dr. (15) Costanza, Mariantonia Dr. (2) Henssen, Anton Prof. Dr. med. (1) Hinz, Michael Dr. (2) Höpken, Uta Elisabeth PD Dr. (1) Keller, Ulrich Dr. med. (1) Kieback, Elisa Dr. (1) Lusatis, Simone (1) Mathas, Stephan Dr. (16) Na, Il-Kang Dr. (1) Obermayer-Wasserscheid, Benedikt Dr. (1) Pezzutto, Antonio Prof. Dr. (1) Scheidereit, Claus Prof. Dr. (3) Schlag, Peter M. Prof. Dr. (1) Uckert, Wolfgang Prof. Dr. (2) Willimsky, Gerald Dr. (4) Wollert-Wulf, Brigitte (2) (-) Beule, Dieter Dr. (1) (-) Daniel, Peter Prof. Dr. (2) (-) Janz, Martin Dr. (10) (-) Leisegang, Matthias Prof. Dr. rer. nat. (1) Bioinformatics and Omics Data Science (2) Bioinformatik der Genregulation (1) (-) Biologie maligner Lymphome (10) Entwicklung Mechanismus-basierter Krebstherapien (1) Genetik und Genomik von Herz- Kreislauferkrankungen (1) Genetik von Angeborenen Herzerkrankungen (1) Genomics (1) Immundysregulationen in der Onkologie (1) Intrazelluläre Proteolyse (1) (-) Molekulare Immunologie und Gentherapie (3) Proteom Dynamik (20) Proteomics (1) RNA Biologie und Posttranscriptionale Regulation (5) Systembiologie von Gen-regulatorischen Elementen (3) Translational Bioinformatics (14) Translationale Onkologie solider Tumore (1) 1999 (1) 2000 (1) (-) 2002 (2) 2003 (3) 2004 (2) 2005 (3) (-) 2006 (5) 2007 (2) (-) 2008 (2) 2009 (3) 2010 (2) 2011 (6) 2012 (2) 2013 (2) 2014 (1) 2015 (5) 2016 (2) 2017 (4) 2018 (2) 2019 (3) 2020 (5) (-) 2021 (4) 2022 (7) 2023 (6) 2024 (1) 13 Ergebnisse: Active Filter: Beule, Dieter Dr.Daniel, Peter Prof. Dr.Janz, Martin Dr.Leisegang, Matthias Prof. Dr. rer. nat.Biologie maligner LymphomeMolekulare Immunologie und Gentherapie 2002200620082021 Sortieren: Treffgenauigkeit Neueste nach älteste Älteste nach neueste 01. Januar 2002 / Int J Cancer Y-box factor YB-1 predicts drug resistance and patient outcome in breast cancer independent of clinically relevant tumor biologic factors HER2, uPA and PAI-1 M. Janz N. Harbeck P. Dettmar U. Berger A. Schmidt K. Juerchott M. Schmitt H.D. Royer 01. November 2006 / Eur J Immunol Designer T cells by T cell receptor replacement D. Sommermeyer J. Neudorfer M. Weinhold M. Leisegang B. Engels E. Noessner M.H. Heemskerk J. Charo D.J. Schendel T. Blankenstein H. Bernhard W. Uckert 01. April 2006 / Cell Death Differ Loss of the tissue-specific proapoptotic BH3-only protein Nbk/Bik is a unifying feature of renal cell carcinoma I. Sturm C. Stephan B. Gillissen R. Siebert M. Janz S. Radetzki K. Jung S. Loening B. Doerken P.T. Daniel 01. Februar 2006 / Nat Immunol Intrinsic inhibition of transcription factor E2A by HLH proteins ABF-1 and Id2 mediates reprogramming of neoplastic B cells in Hodgkin lymphoma S. Mathas M. Janz F. Hummel M. Hummel B. Wollert-Wulf S. Lusatis I. Anagnostopoulos A. Lietz M. Sigvardsson F. Jundt K. Joehrens K. Bommert H. Stein B. Doerken 15. Mai 2006 / Cell Cycle Reprogramming of B lymphoid cells in human lymphoma pathogenesis M. Janz B. Doerken S. Mathas 15. März 2006 / Blood Classical Hodgkin lymphoma is characterized by high constitutive expression of activating transcription factor 3 (ATF3) which promotes viability of Hodgkin/Reed-Sternberg cells M. Janz M. Hummel M. Truss B. Wollert-Wulf S. Mathas K. Joehrens C. Hagemeier K. Bommert H. Stein B. Doerken R.C. Bargou 15. Oktober 2008 / Blood Aberrant expression of the Th2 cytokine IL-21 in Hodgkin lymphoma cells regulates STAT3 signaling and attracts Treg cells via regulation of MIP-3α B. Lamprecht S. Kreher I. Anagnostopoulos K. Joehrens G. Monteleone F. Jundt H. Stein M. Janz B. Doerken S. Mathas 01. September 2008 / Haematologica The pathogenesis of classical Hodgkin's lymphoma: what can we learn from analyses of genomic alterations in Hodgkin and Reed-Sternberg cells? M. Janz S. Mathas 01. November 2002 / Gene Ther Adenoviral transduction of tumor cells induces apoptosis in co-cultured T lymphocytes C. Scholz L. Staerck G. Willimsky T. Blankenstein B. Doerken P.T. Daniel 22. September 2021 / Nat Commun Super-enhancer-based identification of a BATF3/IL-2R-module reveals vulnerabilities in anaplastic large cell lymphoma H.C. Liang M. Costanza N. Prutsch M.W. Zimmerman E. Gurnhofer I.A. Montes-Mojarro B.J. Abraham N. Prokoph S. Stoiber S. Tangermann C. Lobello J. Oppelt I. Anagnostopoulos T. Hielscher S. Pervez W. Klapper F. Zammarchi D.A. Silva K.C. Garcia D. Baker M. Janz N. Schleussner F. Fend Š. Pospíšilová A. Janiková J. Wallwitz D. Stoiber I. Simonitsch-Klupp L. Cerroni S. Pileri L. de Leval D. Sibon V. Fataccioli P. Gaulard C. Assaf F. Knörr C. Damm-Welk W. Woessmann S.D. Turner A.T. Look S. Mathas L. Kenner O. Merkel Seitennummerierung Aktuelle Seite 1 Seite 2 Nächste Seite Next › Letzte Seite Last »
01. Januar 2002 / Int J Cancer Y-box factor YB-1 predicts drug resistance and patient outcome in breast cancer independent of clinically relevant tumor biologic factors HER2, uPA and PAI-1 M. Janz N. Harbeck P. Dettmar U. Berger A. Schmidt K. Juerchott M. Schmitt H.D. Royer
01. November 2006 / Eur J Immunol Designer T cells by T cell receptor replacement D. Sommermeyer J. Neudorfer M. Weinhold M. Leisegang B. Engels E. Noessner M.H. Heemskerk J. Charo D.J. Schendel T. Blankenstein H. Bernhard W. Uckert
01. April 2006 / Cell Death Differ Loss of the tissue-specific proapoptotic BH3-only protein Nbk/Bik is a unifying feature of renal cell carcinoma I. Sturm C. Stephan B. Gillissen R. Siebert M. Janz S. Radetzki K. Jung S. Loening B. Doerken P.T. Daniel
01. Februar 2006 / Nat Immunol Intrinsic inhibition of transcription factor E2A by HLH proteins ABF-1 and Id2 mediates reprogramming of neoplastic B cells in Hodgkin lymphoma S. Mathas M. Janz F. Hummel M. Hummel B. Wollert-Wulf S. Lusatis I. Anagnostopoulos A. Lietz M. Sigvardsson F. Jundt K. Joehrens K. Bommert H. Stein B. Doerken
15. Mai 2006 / Cell Cycle Reprogramming of B lymphoid cells in human lymphoma pathogenesis M. Janz B. Doerken S. Mathas
15. März 2006 / Blood Classical Hodgkin lymphoma is characterized by high constitutive expression of activating transcription factor 3 (ATF3) which promotes viability of Hodgkin/Reed-Sternberg cells M. Janz M. Hummel M. Truss B. Wollert-Wulf S. Mathas K. Joehrens C. Hagemeier K. Bommert H. Stein B. Doerken R.C. Bargou
15. Oktober 2008 / Blood Aberrant expression of the Th2 cytokine IL-21 in Hodgkin lymphoma cells regulates STAT3 signaling and attracts Treg cells via regulation of MIP-3α B. Lamprecht S. Kreher I. Anagnostopoulos K. Joehrens G. Monteleone F. Jundt H. Stein M. Janz B. Doerken S. Mathas
01. September 2008 / Haematologica The pathogenesis of classical Hodgkin's lymphoma: what can we learn from analyses of genomic alterations in Hodgkin and Reed-Sternberg cells? M. Janz S. Mathas
01. November 2002 / Gene Ther Adenoviral transduction of tumor cells induces apoptosis in co-cultured T lymphocytes C. Scholz L. Staerck G. Willimsky T. Blankenstein B. Doerken P.T. Daniel
22. September 2021 / Nat Commun Super-enhancer-based identification of a BATF3/IL-2R-module reveals vulnerabilities in anaplastic large cell lymphoma H.C. Liang M. Costanza N. Prutsch M.W. Zimmerman E. Gurnhofer I.A. Montes-Mojarro B.J. Abraham N. Prokoph S. Stoiber S. Tangermann C. Lobello J. Oppelt I. Anagnostopoulos T. Hielscher S. Pervez W. Klapper F. Zammarchi D.A. Silva K.C. Garcia D. Baker M. Janz N. Schleussner F. Fend Š. Pospíšilová A. Janiková J. Wallwitz D. Stoiber I. Simonitsch-Klupp L. Cerroni S. Pileri L. de Leval D. Sibon V. Fataccioli P. Gaulard C. Assaf F. Knörr C. Damm-Welk W. Woessmann S.D. Turner A.T. Look S. Mathas L. Kenner O. Merkel